Correlation Between Crispr Therapeutics and Royalty Pharma

Can any of the company-specific risk be diversified away by investing in both Crispr Therapeutics and Royalty Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crispr Therapeutics and Royalty Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Crispr Therapeutics AG and Royalty Pharma Plc, you can compare the effects of market volatilities on Crispr Therapeutics and Royalty Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crispr Therapeutics with a short position of Royalty Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crispr Therapeutics and Royalty Pharma.

Diversification Opportunities for Crispr Therapeutics and Royalty Pharma

0.24

Correlation Coefficient

Crispr Therapeutics  Royalty Pharma

Modest diversification

The 3 months correlation between Crispr and Royalty is 0.24. Overlapping area represents the amount of risk that can be diversified away by holding Crispr Therapeutics AG and Royalty Pharma Plc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Royalty Pharma Plc and Crispr Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crispr Therapeutics AG are associated (or correlated) with Royalty Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Royalty Pharma Plc has no effect on the direction of Crispr Therapeutics i.e., Crispr Therapeutics and Royalty Pharma go up and down completely randomly.

Pair Corralation between Crispr Therapeutics and Royalty Pharma

Given the investment horizon of 90 days Crispr Therapeutics AG is expected to generate 2.49 times more return on investment than Royalty Pharma. However, Crispr Therapeutics is 2.49 times more volatile than Royalty Pharma Plc. It trades about 0.0 of its potential returns per unit of risk. Royalty Pharma Plc is currently generating about -0.04 per unit of risk. If you would invest  5,312  in Crispr Therapeutics AG on September 25, 2024 and sell it today you would lose (1,221) from holding Crispr Therapeutics AG or give up 22.99% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	99.76%
Values	Daily Returns

Crispr Therapeutics AG  vs.  Royalty Pharma Plc

Crispr Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Crispr Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest unfluctuating performance, the Stock's basic indicators remain invariable and the latest agitation on Wall Street may also be a sign of long-running gains for the enterprise retail investors.

Royalty Pharma Plc

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Royalty Pharma Plc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Pair Trading with Crispr Therapeutics and Royalty Pharma

The main advantage of trading using opposite Crispr Therapeutics and Royalty Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crispr Therapeutics position performs unexpectedly, Royalty Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Royalty Pharma will offset losses from the drop in Royalty Pharma's long position.

The idea behind Crispr Therapeutics AG and Royalty Pharma Plc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.